vs
Side-by-side financial comparison of Beta Bionics, Inc. (BBNX) and Neuronetics, Inc. (STIM). Click either name above to swap in a different company.
Neuronetics, Inc. is the larger business by last-quarter revenue ($41.8M vs $27.6M, roughly 1.5× Beta Bionics, Inc.). Neuronetics, Inc. runs the higher net margin — -17.2% vs -79.3%, a 62.0% gap on every dollar of revenue. On growth, Neuronetics, Inc. posted the faster year-over-year revenue change (85.7% vs 56.6%).
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
BBNX vs STIM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $27.6M | $41.8M |
| Net Profit | $-21.9M | $-7.2M |
| Gross Margin | 59.5% | 52.0% |
| Operating Margin | -47.4% | -12.1% |
| Net Margin | -79.3% | -17.2% |
| Revenue YoY | 56.6% | 85.7% |
| Net Profit YoY | 23.6% | 43.2% |
| EPS (diluted) | $-0.49 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $27.6M | — | ||
| Q4 25 | $32.1M | $41.8M | ||
| Q3 25 | $27.3M | $37.3M | ||
| Q2 25 | $23.2M | $38.1M | ||
| Q1 25 | $17.6M | $32.0M | ||
| Q4 24 | — | $22.5M | ||
| Q3 24 | — | $18.5M | ||
| Q2 24 | — | $16.4M |
| Q1 26 | $-21.9M | — | ||
| Q4 25 | $-13.5M | $-7.2M | ||
| Q3 25 | $-14.2M | $-9.0M | ||
| Q2 25 | $-16.9M | $-10.1M | ||
| Q1 25 | $-28.7M | $-12.7M | ||
| Q4 24 | — | $-12.7M | ||
| Q3 24 | — | $-13.3M | ||
| Q2 24 | — | $-9.8M |
| Q1 26 | 59.5% | — | ||
| Q4 25 | 59.0% | 52.0% | ||
| Q3 25 | 55.5% | 45.9% | ||
| Q2 25 | 53.8% | 46.6% | ||
| Q1 25 | 50.9% | 49.2% | ||
| Q4 24 | — | 66.2% | ||
| Q3 24 | — | 75.6% | ||
| Q2 24 | — | 74.0% |
| Q1 26 | -47.4% | — | ||
| Q4 25 | -50.2% | -12.1% | ||
| Q3 25 | -62.5% | -19.6% | ||
| Q2 25 | -85.5% | -21.1% | ||
| Q1 25 | -105.7% | -34.4% | ||
| Q4 24 | — | -51.0% | ||
| Q3 24 | — | -41.7% | ||
| Q2 24 | — | -51.7% |
| Q1 26 | -79.3% | — | ||
| Q4 25 | -41.9% | -17.2% | ||
| Q3 25 | -52.1% | -24.3% | ||
| Q2 25 | -72.6% | -26.6% | ||
| Q1 25 | -162.5% | -39.6% | ||
| Q4 24 | — | -56.4% | ||
| Q3 24 | — | -72.0% | ||
| Q2 24 | — | -59.8% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-0.16 | $-0.10 | ||
| Q3 25 | $-0.33 | $-0.13 | ||
| Q2 25 | $-0.39 | $-0.15 | ||
| Q1 25 | $-0.93 | $-0.21 | ||
| Q4 24 | — | $-0.34 | ||
| Q3 24 | — | $-0.44 | ||
| Q2 24 | — | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $199.5M | $28.1M |
| Total DebtLower is stronger | — | $65.8M |
| Stockholders' EquityBook value | $271.2M | $22.4M |
| Total Assets | $304.4M | $141.6M |
| Debt / EquityLower = less leverage | — | 2.94× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $199.5M | — | ||
| Q4 25 | $219.1M | $28.1M | ||
| Q3 25 | $228.7M | $28.0M | ||
| Q2 25 | $249.7M | $11.0M | ||
| Q1 25 | $231.5M | $20.2M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | — | $20.9M | ||
| Q2 24 | — | $42.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $65.8M | ||
| Q3 25 | — | $65.7M | ||
| Q2 25 | — | $55.5M | ||
| Q1 25 | — | $55.3M | ||
| Q4 24 | — | $55.2M | ||
| Q3 24 | — | $46.0M | ||
| Q2 24 | — | $59.8M |
| Q1 26 | $271.2M | — | ||
| Q4 25 | $287.6M | $22.4M | ||
| Q3 25 | $294.8M | $27.4M | ||
| Q2 25 | $301.6M | $27.1M | ||
| Q1 25 | $313.8M | $35.5M | ||
| Q4 24 | — | $27.7M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $19.4M |
| Q1 26 | $304.4M | — | ||
| Q4 25 | $328.7M | $141.6M | ||
| Q3 25 | $330.0M | $145.5M | ||
| Q2 25 | $330.0M | $134.7M | ||
| Q1 25 | $338.0M | $142.0M | ||
| Q4 24 | — | $140.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.94× | ||
| Q3 25 | — | 2.40× | ||
| Q2 25 | — | 2.05× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 1.99× | ||
| Q3 24 | — | 4.90× | ||
| Q2 24 | — | 3.08× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $908.0K |
| Free Cash FlowOCF − Capex | — | $692.0K |
| FCF MarginFCF / Revenue | — | 1.7% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-21.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-8.6M | $908.0K | ||
| Q3 25 | $-8.7M | $-785.0K | ||
| Q2 25 | $-13.6M | $-3.5M | ||
| Q1 25 | $-20.0M | $-17.0M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | — | $-5.4M | ||
| Q2 24 | — | $-5.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-10.5M | $692.0K | ||
| Q3 25 | $-10.0M | $-899.0K | ||
| Q2 25 | $-15.4M | $-3.8M | ||
| Q1 25 | $-20.3M | $-17.2M | ||
| Q4 24 | — | $-8.7M | ||
| Q3 24 | — | $-5.8M | ||
| Q2 24 | — | $-5.6M |
| Q1 26 | — | — | ||
| Q4 25 | -32.8% | 1.7% | ||
| Q3 25 | -36.7% | -2.4% | ||
| Q2 25 | -66.2% | -9.9% | ||
| Q1 25 | -115.1% | -53.8% | ||
| Q4 24 | — | -38.6% | ||
| Q3 24 | — | -31.3% | ||
| Q2 24 | — | -34.0% |
| Q1 26 | — | — | ||
| Q4 25 | 5.9% | 0.5% | ||
| Q3 25 | 4.7% | 0.3% | ||
| Q2 25 | 7.7% | 0.7% | ||
| Q1 25 | 1.9% | 0.7% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | 3.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
